Treatment options for HBV include antiviral medications such as tenofovir and entecavir, which can suppress viral replication and reduce liver damage. For HCV, direct-acting antivirals (DAAs) have revolutionized treatment, offering cure rates exceeding 95%. Despite these advancements, treatment does not eliminate the risk of liver cancer in those with already established liver damage.
